Checkpoint Therapeutics Inc Quick Ratio (CKPT) starting from the first quarter 2025 to first quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Checkpoint Therapeutics inc   (NASDAQ: CKPT)

Checkpoint Therapeutics Inc 's Quick Ratio

CKPT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Checkpoint Therapeutics Inc 's Cash & cash equivalent grew by 400.33 % in the Q1 2025 sequentially, while Current Liabilities decreased, this led to improvement in Checkpoint Therapeutics Inc 's Quick Ratio to 1.85, Quick Ratio remained below Checkpoint Therapeutics inc average.

Within Major Pharmaceutical Preparations industry 263 other companies have achieved higher Quick Ratio than Checkpoint Therapeutics Inc in first quarter 2025. While Quick Ratio total ranking has improved so far during the Q1 2025 to 1001, from total ranking in the fourth quarter 2024 at 2266.

Explain Quick Ratio?
How much Cash & cash equivalents CKPT´s has?
What are CKPT´s Current Liabilities?




CKPT Quick Ratio (Mar 31 2025)
Q1
(Dec 31 2024)
Q4
(Sep 30 2024)
Q3
(Jun 30 2024)
Q2
(Mar 31 2024)
Q1
Y / Y Current Liabilities Change -19.6 % 9.07 % -16.42 % -32.24 % -9.18 %
Y / Y Cash & cash equivalent Change 193.94 % 34.01 % 165.41 % -33.28 % 131.96 %
Quick Ratio MRQ 1.85 0.33 0.26 0.23 0.51
CKPT's Total Ranking # 1001 # 2266 # 2675 # 2264 # 1477
Seq. Current Liabilities Change -11.08 % 13.1 % -17.04 % -3.63 % 20.62 %
Seq. Cash & cash equivalent Change 400.33 % 40.42 % -5.01 % -55.96 % 128.1 %



Quick Ratio first quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 264
Healthcare Sector # 454
Overall Market # 1001


Quick Ratio Statistics
High Average Low
7.5 2.32 0.08
(Mar 31 2017)   (Sep 30 2023)




Financial Statements
Checkpoint Therapeutics Inc 's Current Liabilities $ 18 Millions Visit CKPT's Balance sheet
Checkpoint Therapeutics Inc 's Cash & cash equivalent $ 33 Millions Visit CKPT's Balance sheet
Source of CKPT's Sales Visit CKPT's Sales by Geography


Cumulative Checkpoint Therapeutics Inc 's Quick Ratio

CKPT's Quick Ratio for the trailling 12 Months

CKPT Quick Ratio

(Mar 31 2025)
12 Months
(Dec 31 2024)
12 Months
(Sep 30 2024)
12 Months
(Jun 30 2024)
12 Months
(Mar 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -17.5 % -14.89 % -19.31 % -17.2 % -0.14 %
Y / Y Cash & cash equivalent TTM Growth 94.39 % 44.98 % -1.09 % -48.92 % -62.86 %
Quick Ratio TTM 0.64 0.34 0.32 0.27 0.27
Total Ranking TTM # 4273 # 2800 # 3313 # 2863 # 1395
Seq. Current Liabilities TTM Growth -5.34 % 2.09 % -4.19 % -10.9 % -2.35 %
Seq. Cash & cash equivalent TTM Growth 79.28 % 6.49 % 12.8 % -9.74 % 33.72 %


On the trailing twelve months basis CKPT Cash & cash equivalent more than doubled by 193.94 % in Q1 2025 year on year, while Current Liabilities fell to $18 millions, this led to increase in in Checkpoint Therapeutics Inc 's Quick Ratio to 0.64, Quick Ratio remained below CKPT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 524 other companies have achieved higher Quick Ratio than Checkpoint Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2024 from 2800 to 4273.

Explain Quick Ratio?
How much Cash & cash equivalents CKPT´s has?
What are CKPT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 525
Healthcare Sector # 1049
Within the Market # 4273


trailing twelve months Quick Ratio Statistics
High Average Low
4.57 1.75 0.19
(Mar 31 2018)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2025 MRQ Cash & cash equivalentMar 31 2025 MRQ Current Liabilities
Forte Biosciences Inc   5.08 $ 45.856  Millions$ 9.032  Millions
Madrigal Pharmaceuticals Inc   5.07 $ 843.068  Millions$ 166.221  Millions
Prelude Therapeutics Inc  5.01 $ 99.074  Millions$ 19.787  Millions
Cogent Biosciences Inc   4.98 $ 245.661  Millions$ 49.318  Millions
Aldeyra Therapeutics Inc   4.94 $ 39.707  Millions$ 8.031  Millions
Hepion Pharmaceuticals Inc   4.90 $ 4.586  Millions$ 0.936  Millions
Silo Pharma Inc  4.90 $ 5.451  Millions$ 1.113  Millions
Aclaris Therapeutics Inc   4.90 $ 105.314  Millions$ 21.514  Millions
Pepgen Inc   4.79 $ 97.781  Millions$ 20.431  Millions
Genelux Corporation  4.77 $ 35.102  Millions$ 7.352  Millions
Corvus Pharmaceuticals Inc   4.76 $ 44.212  Millions$ 9.279  Millions
Scynexis Inc   4.76 $ 40.607  Millions$ 8.532  Millions
Cns Pharmaceuticals Inc   4.69 $ 13.048  Millions$ 2.779  Millions
Abeona Therapeutics Inc   4.68 $ 84.155  Millions$ 17.983  Millions
Transcode Therapeutics Inc   4.65 $ 11.681  Millions$ 2.510  Millions
Mural Oncology Plc  4.65 $ 107.682  Millions$ 23.153  Millions
United Therapeutics Corporation  4.60 $ 3,321.300  Millions$ 721.500  Millions
Lantern Pharma Inc   4.60 $ 19.722  Millions$ 4.286  Millions
Kiora Pharmaceuticals Inc   4.57 $ 24.106  Millions$ 5.275  Millions
Bullfrog Ai Holdings Inc   4.53 $ 3.802  Millions$ 0.839  Millions
Maravai Lifesciences Holdings Inc   4.51 $ 285.053  Millions$ 63.158  Millions
Kairos Pharma Ltd   4.49 $ 3.616  Millions$ 0.805  Millions
Q32 Bio Inc   4.49 $ 65.483  Millions$ 14.579  Millions
Arvinas Inc   4.46 $ 954.300  Millions$ 214.000  Millions
Arcturus Therapeutics Holdings Inc   4.39 $ 216.948  Millions$ 49.409  Millions
Damora Therapeutics Inc   4.33 $ 11.939  Millions$ 2.755  Millions
Hutchmed china Limited  4.33 $ 1,367.275  Millions$ 315.775  Millions
Milestone Pharmaceuticals Inc   4.32 $ 55.958  Millions$ 12.963  Millions
Sinovac Biotech Ltd  4.31 $ 6,639.502  Millions$ 1,540.365  Millions
Cocrystal Pharma Inc   4.27 $ 6.921  Millions$ 1.622  Millions

Date modified: 2026-09-26T07:30:29+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.